VA launches psilocybin study for depression and PTSD
The Department of Veterans Affairs has launched a major clinical trial to study whether psilocybin, the active compound in psychedelic mushrooms, can effectively treat veterans suffering from treatment-resistant depression and post-traumatic stress disorder. The study, called the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression or PIVOT, will enroll at least 240 veterans across five VA medical centers and run through June 2031. VA Secretary Doug Collins emphasized that the initiative reflects the department's commitment to exploring new treatment options for veterans whose mental health conditions have not responded to currently available therapies.
This research builds on promising early findings from a small Ohio State University study published in July that examined psilocybin treatment for severe PTSD in veterans. In that 12-person trial, participants received eight hours of psychotherapy along with two doses of synthetic psilocybin and integrative therapy. Seventy-five percent of participants no longer met clinical criteria for PTSD after treatment, with no serious adverse effects reported. The most common side effects were headache, anxiety, and dizziness, and notably, no participants experienced suicidal ideation or behavior during the study.
The PIVOT trial will specifically target veterans with major depressive disorder who have not responded to existing treatments, including those with or without a concurrent PTSD diagnosis. This represents a significant population among disabled veterans, many of whom have exhausted traditional treatment options including medication and various forms of therapy without achieving meaningful relief. The study will use a double-blind, randomized design, meaning neither participants nor researchers will initially know who receives psilocybin versus a placebo.
Veterans enrolled in the study will receive one dose of psilocybin or placebo along with therapeutic support, followed by a second dose one month later. Researchers will evaluate participants two to four weeks after each session and conduct follow-up assessments six months after participation concludes. The five participating VA facilities are the Birmingham VA Health Care System and Tuscaloosa VA Medical Center in Alabama, the VA Portland Health Care System in Oregon, Cpl. Michael Crescenz VA Medical Center in Philadelphia, and VA Puget Sound Health Care System in Seattle. All treatments will use pharmaceutical-grade drugs administered in safe, controlled clinical settings.
This trial follows an executive order signed by President Trump in April directing the FDA to accelerate review of psychedelic therapies for mental health conditions and requiring coordination between the FDA, Department of Health and Human Services, and VA on psychedelic research. The VA currently has staff involved in 20 clinical trials focused on psychedelic treatments, including studies of MDMA and LSD. This represents a significant shift in federal research priorities, though the FDA rejected an application to approve MDMA for PTSD treatment in 2024, citing the need for additional safety and efficacy data.
For disabled veterans struggling with treatment-resistant depression and PTSD, this study represents both hope and a reminder of the long timeline required for new treatments to become available. While psychedelic therapy shows promise, it remains years away from potential approval as a standard VA treatment option. The research is particularly relevant for veterans with service-connected mental health conditions who have cycled through multiple medications and therapies without sustained improvement.
VA officials strongly caution veterans against self-medicating with psychedelics or replacing prescribed treatments with unprescribed substances. Veterans currently struggling with depression or PTSD should continue working with their VA mental health providers and utilizing proven, evidence-based treatments already available through the VA system. Those interested in participating in psychedelic research trials should speak with their VA provider about eligibility and enrollment opportunities at the five participating medical centers.